Skip to main content

Table 3 Hepatic parenchymal changes and pathology results in the patients with MR elastography

From: Imaging features of COVID-19-associated secondary sclerosing cholangitis on magnetic resonance cholangiopancreatography: a retrospective analysis

 

Hepatic parenchymal changes on imaging

Pathology findings (fibrosis grade)

Case 1 (3.2 kPa)

Patchy arterial phase hyperenhancement

Hyperintense signal changes on DWI

Diffusely reduced signal in the hepatobiliary phase

Mild portal and periportal fibrosis without bridging septae (F1)

Case 2 (4.2 kPa)

Patchy reduced signal in the hepatobiliary phase

Portal fibrosis, mild pericentral and pericellular fibrosis without bridging septae (F1)

Case 3 (6.4 kPa)

Patchy arterial phase hyperenhancement

Patchy peripheral and subcapsular hyperintense signal changes on T2-weighted images

Patchy reduced signal in the hepatobiliary phase

Rounded liver contours

Caudate lobe hypertrophy

N/A

Case 4 (11.4 kPa)

Patchy arterial phase hyperenhancement

Caudate lobe hypertrophy

Portal and pericellular fibrosis without bridging septae (F1)

  1. The depicted kPa values correspond to the liver stiffness values assessed with MR elastography
  2. Cases 1, 2 and 3 received MRI with the hepatospecific contrast agent gadoxetate disodium, Case 4 received the extracellular contrast agent gadoteric acid